ClinicalTrials.gg
CompletedNCT01392716Updated Nov 2, 2016

A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

A Phase 2 interventional study of rituximab [MabThera/Rituxan] in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 16 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
68th of 171
48 · median 38
Started
1997
with 3 others
Phase 2
94 of 178
3 open now
Registered
122nd of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 68th largest by enrollment of the 171 interventional ones that give a count, is one of 4 that started in 1997, is one of 94 in phase 2, and was the 122nd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 18-75 years of age
  • Newly diagnosed non-bulky follicular non-Hodgkin's lymphoma
  • >/=1
  • No prior treatment (no or radiotherapy)

Exclusion criteria

Exclusion Criteria:

  • Transformed follicular lymphoma
  • Cerebral or meningeal lymphomaotus localization
  • Uncontrolled concurrent infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Single arm

    Drug: rituximab [MabThera/Rituxan]

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    375 mg/m2 intravenously once a week for 4 weeks

06

What researchers measure

Primary outcomes

  1. Overall objective complete response rate

    Time frame: Day 50

  2. Overall objective partial response rate

    Time frame: Day 50

Secondary outcomes

  1. Progression-free survival

    Time frame: 7 years

  2. Overall survival

    Time frame: 7 years

  3. Duration of response

    Time frame: 7 years

  4. Safety: Incidence of adverse events

    Time frame: 7 years

  5. Level of biological marker bcl2 in peripheral blood and bone marrow

    Time frame: 7 years

07

Study locations

16 sites
  • Angers, 49033, France
  • Besancon, 25030, France
  • Bordeaux, 33076, France
  • Clamart, 92141, France
  • Creteil, 94010, France
  • Le Mans, 72015, France
  • Lyon, 69373, France
  • Nantes, 44093, France
  • Nice, 06202, France
  • Paris, 75475, France
  • Paris, 75571, France
  • Pierre Benite, 69495, France
  • Poitiers, 86021, France
  • Rouen, 76038, France
  • Tours, 37044, France
  • Vandoeuvre-les-nancy, 54511, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1997, a primary completion of Feb 2006 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2011
First posted
Jul 12, 2011
Start
Oct 1997
Primary completionActual
Feb 2006
CompletionActual
Feb 2006
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01392716
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 12, 2011
Start date
Oct 1997
Primary completion
Feb 2006
Completion
Feb 2006
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion